Psyence BioMed Emphasizes GMP Ibogaine Manufacturing as U.S. Prepares Regulatory Action
The U.S. administration is preparing an executive order to evaluate ibogaine’s safety and therapeutic potential in PTSD and addiction treatment. Psyence BioMed highlights its global leadership in GMP-compliant ibogaine manufacturing and ethically sourced African supply chain through PsyLabs to support upcoming clinical research and regulatory pathways.
1. Planned U.S. Executive Order on Ibogaine Research
The administration is drafting an executive order to further evaluate ibogaine’s safety and therapeutic potential in treating PTSD, addiction and other neurological conditions.
2. GMP-Compliant Manufacturing Capability
Psyence BioMed operates a GMP-compliant manufacturing facility through PsyLabs, positioning itself as a leading supplier of purified ibogaine and derivatives for global clinical trials.
3. Ethical Sourcing from African Ecosystem
The company has established an ethically sourced ibogaine supply chain within the compound’s native African ecosystem to ensure sustainability, traceability and respect for traditional practices.
4. Strategic Growth Positioning
With integrated GMP production, ethical sourcing and clinical development capabilities, Psyence BioMed is strategically positioned to support upcoming regulatory frameworks and expand its psychedelic-based therapeutic pipeline.